27 / 42
CheckMate 012: First-Line Nivolumab + Chemotherapy in NSCLC
3-Year KM Estimates of OS Rates
•
3-year KM estimates of OS rates by chemotherapy regimen: nivolumab + pemetrexed–cisplatin (non-SQ only), 27%; nivolumab
+ paclitaxel–carboplatin (any histology), 32%; nivolumab + gemcitabine–cisplatin (SQ only), 8%
27
No. of patients at risk
56
54
40
30
20
16
13
9
4
1
0
1-year OS: 71%
2-year OS: 37%
3-year OS: 25%
a
100
80
60
40
20
0
0
6
12
18
24
30
36
42
48
54 57
OS (%)
Time since first dose (months)
a
Between 2 and 3 years, there were 6 deaths due to disease and 1 patient was censored due to loss to follow-up; KM = Kaplan–Meier